Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Badry Bursulaya

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Bioconjugate Chemistry|November 21, 2015
Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Phosphopantetheinyl TransferasesJan Grünewald, Heath E Klock, Susan E Cellitti, et al.
Journal of Medicinal Chemistry|November 18, 2017
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)David C Tully, Paul V Rucker, Donatella Chianelli, et al.
Journal of Medicinal Chemistry|March 27, 2014
Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacyDean P Phillips, Wenqi Gao, Yang Yang, et al.
ACS Medicinal Chemistry Letters|December 17, 2021
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine RET InhibitorsCasey J N Mathison, Yang Yang, John Nelson, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
Nature Chemical Biology|May 6, 2008
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motilityNobutaka Kato, Tomoyo Sakata, Ghislain Breton, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Efficacy and Tolerability of Pyrazolo[1,5-<i>a</i>]pyrimidine RET Kinase Inhibitors for the Treatment of Lung AdenocarcinomaCasey J N Mathison, Donatella Chianelli, Paul V Rucker, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory DiseasesXiaohui He, Sara Da Ros, John Nelson, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Bioconjugate Chemistry|November 21, 2015
Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Phosphopantetheinyl TransferasesJan Grünewald, Heath E Klock, Susan E Cellitti, et al.
Journal of Medicinal Chemistry|November 18, 2017
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)David C Tully, Paul V Rucker, Donatella Chianelli, et al.
Journal of Medicinal Chemistry|March 27, 2014
Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacyDean P Phillips, Wenqi Gao, Yang Yang, et al.
ACS Medicinal Chemistry Letters|December 17, 2021
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine RET InhibitorsCasey J N Mathison, Yang Yang, John Nelson, et al.
Journal of Medicinal Chemistry|July 20, 2016
Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung CancersGérald Lelais, Robert Epple, Thomas H Marsilje, et al.
Nature|June 3, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsYong Jia, Cai-Hong Yun, Eunyoung Park, et al.
Nature Chemical Biology|May 6, 2008
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motilityNobutaka Kato, Tomoyo Sakata, Ghislain Breton, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Efficacy and Tolerability of Pyrazolo[1,5-<i>a</i>]pyrimidine RET Kinase Inhibitors for the Treatment of Lung AdenocarcinomaCasey J N Mathison, Donatella Chianelli, Paul V Rucker, et al.
Cancer Research|January 31, 2016
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorYong Jia, Jose Juarez, Jie Li, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory DiseasesXiaohui He, Sara Da Ros, John Nelson, et al.
Pageof 5